


(51) International Patent Classification ⁶ : A61K 9/36		A1	(11) International Publication Number: WO 96/10995
			(43) International Publication Date: 18 April 1996 (18.04.96)
(21) International Application Number: PCT/US95/12934		(74) Agents: EARLEY, John, F., A. et al.; 86 The Commons at Valley Forge East, 1288 Valley Forge Road, P.O. Box 750, Valley Forge, PA 19482-0750 (US).	
(22) International Filing Date: 6 October 1995 (06.10.95)			
(30) Priority Data: 08/319,987 7 October 1994 (07.10.94) US		(81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).	
(60) Parent Application or Grant (63) Related by Continuation US Filed on 08/319,987 (CON) 7 October 1994 (07.10.94)		Published With international search report.	
(71) Applicant (for all designated States except US): BERWIND PHARMACEUTICAL SERVICES, INC. [US/US]; Moyer Boulevard, West Point, PA 19486 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): MEHRA, Dev, K. [US/US]; 20 Farmhouse Lane, Furlong, PA 18925 (US). RAMIREDDY, Chittamuru [IN/US]; Apartment #J2-15, 1158 West Main Street, Landsdale, PA 19446 (US). TANG, Li-Juan [CN/US]; 637 Caroline Drive, Norristown, PA 19401 (US). PORTER, Stuart, C. [GB/US]; 675 Brighton Drive, Hatfield, PA 19440 (US).			

(54) Title: ENTERIC FILM COATING COMPOSITIONS, METHOD OF COATING THEREWITH, AND COATED FORMS



A non-toxic edible enteric film coating dry powder composition for use in making an aqueous enteric coating suspension which may be used in coating pharmaceutical tablets and the like comprises an enteric film forming polymer, a detackifier, a viscosity modifier, and an alkalizing/anti-coagulating agent. Advantageously, the inventive dry powder compositions may include a solid plasticizer, a lubricant, an anti-caking agent, a liquid plasticizer, and a pigment.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

BACKGROUND OF THE INVENTION

Enteric coating solutions that require organic solvents have been used in the past. However, because of the problems associated with the use of organic solvents (i.e., pollution of the atmosphere, safety and hygiene problems for workers, danger of fire and explosion, and expensive equipment requirements to limit or reduce the danger of fire or explosion), aqueous enteric film coating suspensions, such as the COATERIC enteric film coating system of Colorcon, West Point, Pennsylvania, were developed. The COATERIC system is disclosed in Colorcon U.S. Patent No. 4,556,552, which issued on December 3, 1985, and in Colorcon U.S. Patent No. 4,704,295 which issued on November 3, 1987, both of which are incorporated herein by reference.

Other known aqueous enteric film coating systems include an aqueous dispersion of acrylic resins, for example, polymethacryl methacrylate copolymer, and dispersions of acetates, for example, cellulose acetate phthalate.

A problem associated with the known aqueous enteric coating suspensions is tackiness of the coating.

Another problem with the known aqueous enteric coating systems is that they require at least three processing steps to form the enteric coating suspension. For instance, with the EUDRAGIT system, plasticizer, antifoam, and talc are mixed stepwise into the EUDRAGIT dispersion. With the AQUATERIC - cellulose acetate phthalate dispersion system, the AQUATERIC powder is dispersed in water, followed by stepwise addition of plasticizer, and Tween 80 to form the AQUATERIC suspension. With the COATERIC system, the COATERIC powder, an antifoam, and ammonium hydroxide are mixed into water to form the COATERIC suspension. The need for three processing steps is a drawback because the more processing steps there are, the higher the chances of processing error occurring.

In the Colorcon U.S. Patent Nos. 4,556,552 and 4,704,295, Colorcon's COATERIC non-toxic edible enteric film coating dry powder, which comprises polyvinyl acetate phthalate (PVAP), a water-soluble plasticizer, an auxiliary film-forming suspending polymeric agent for the PVAP, and pigment particles, is mixed into water, and after the enteric dry powder is thoroughly wetted, an ammonium hydroxide solution is added to form an enteric coating suspension. Although the COATERIC coating

suspension forms a very good enteric coating, the COATERIC suspension has the smell of ammonium hydroxide.

SUMMARY OF THE INVENTION

5 It is an object of the invention to provide an enteric coating that is less tacky than known aqueous-based enteric film coatings.

 Another object of the invention to provide an aqueous enteric coating suspension that only
10 requires two processing steps to form the enteric coating suspension.

 Another object of the invention is to provide an aqueous enteric coating suspension that does not have the odor of ammonium hydroxide.

15 Another object of the invention is to provide a pre-plasticized powder blend enteric coating composition.

 These and other objects are accomplished by our invention, which is described below.

20 BRIEF DESCRIPTION OF THE DRAWINGS

 Fig. 1 shows a graph of test results regarding percent drug dissolved (average of 6 dissolutions) versus time (minutes), for aspirin cores coated in accordance with Example 1.

DETAILED DESCRIPTION OF THE INVENTION

A non-toxic edible enteric film coating dry powder composition for use in making an aqueous enteric coating suspension which may be used in coating pharmaceutical tablets and the like comprises an enteric film forming polymer, a detackifier, a viscosity modifier, and an alkalizing/anti-coagulating agent. In a particularly preferred embodiment, the inventive non-toxic edible enteric film coating dry powder composition also includes a solid plasticizer.

Advantageously, the inventive dry powder compositions may include a lubricant, an anti-caking agent, a liquid plasticizer, and a pigment.

A method of making the inventive non-toxic edible film coating dry powder composition comprises the steps of mixing an enteric film forming polymer with a detackifier, a viscosity modifier, and an anti-coagulating/alkalizing agent, and optionally with one or more of the following components, until a dry homogeneous powder mixture is produced: a solid plasticizer, a lubricant, an anti-caking agent, a liquid plasticizer, and a pigment. The resulting enteric film coating dry powder composition is readily dispersible in d i n i z e d

water to form a liquid enteric coating suspension and is ready to use in 30 to 45 minutes.

5 The invention also includes an aqueous enteric coating suspension for making an enteric coating for pharmaceutical tablets and the like which comprises an enteric film forming polymer, a detackifier, a viscosity modifier, an alkalizing agent, a plasticizer, and an antifoaming agent mixed into water. Advantageously, the inventive suspension may
10 include an optional lubricant, an optional anti-caking agent, and/or an optional pigment.

A method of making the aqueous enteric coating suspension of the invention comprises mixing the anti-foaming agent into water, mixing the inventive
15 enteric dry powder composition, or the individual ingredients of the inventive enteric dry powder composition separately, into the water, and stirring until a homogeneous suspension is produced. When using an embodiment of the inventive enteric dry
20 powder composition that does not have a plasticizer mixed into it, a plasticizer, preferably a liquid plasticizer, is mixed into the water, preferably after the step of mixing the anti-foam into the water.

The inventive suspension may include a solid plasticizer in combination with a liquid plasticizer. In such a suspension, the liquid plasticizer may be mixed into the enteric dry powder coating composition to become part of the enteric dry powder coating composition of the invention, or the liquid plasticizer may be added separately to the water when preparing the inventive suspension.

The invention also includes a method of coating substrates such as pharmaceutical dosage forms like tablets and the like with a non-toxic edible enteric film coating, which comprises the steps of forming the inventive aqueous enteric coating suspension as discussed above, applying the inventive aqueous coating suspension onto the substrates to form a film coating on the substrates, and drying the film coating on said substrates.

The enteric film forming polymer is PVAP-T (titanized polyvinyl acetate phthalate), PVAP-J (polyvinyl acetate phthalate which has been jet milled), HPMCP (hydroxypropyl methylcellulose phthalate), HPMCAS (hydroxypropyl methylcellulose acetate succinate), or CAP (cellulose acetate phthalate). The titanized polyvinyl acetate phthalate (PVAP-T), comprises about 10% titanium dioxide mixed into polyvinyl acetate phthalate

(PVAP), while it is being made. A preferred enteric polymer is PVAP-T.

Preferably, the enteric polymer has a particle size such that 90% of the polymer particles are under 25 microns, and more preferably, under 13 microns.

The enteric polymer is about 65-85% by weight of the dry powder composition, and is preferably in the range of about 65-81% by weight of the dry powder composition.

The detackifier is talc, aluminum hydrate, or mixtures thereof. The detackifier is about 5-15% by weight of the dry powder composition, and is preferably in the range of about 6-12% by weight of the dry powder composition.

The viscosity modifier is sodium alginate, hydroxypropyl methylcellulose (HPMC), hydroxyethylcellulose (HEC), sodium carboxymethylcellulose (sodium CMC), polyvinylpyrrolidone (PVP), Konjac flour, carrageenan, xanthan gum, other hydrophilic polymers, or mixtures thereof. The viscosity modifier is present in the dry powder composition to assist in the forming of a film on the tablets and to act as a suspending agent for the insoluble components in the coating suspension, as well as

adding viscosity to the coating suspension. The viscosity modifier helps the coating to adhere to the tablet surface while the enteric polymer particles are fusing to form a film. In other words, the viscosity modifier makes the coating suspension thicker and thereby inhibits settlement and acts as a suspending agent, and also acts as a film former. A preferred viscosity modifier is a medium viscosity grade of sodium alginate (e.g., Kelco Manugel A3B812 sodium alginate).

The viscosity modifier is about 0.5 to 7% by weight of the dry powder composition, and is preferably in the range of about 1-6% by weight of the dry powder composition.

The alkalizing agent is a bicarbonate, a carbonate, a phosphate, or a hydroxide of sodium or potassium, magnesium carbonate, magnesium hydroxide, ammonium carbonate, ammonium bicarbonate, magnesium oxide, calcium hydroxide, or mixtures thereof.

The alkalizing agent is about 1-15% by weight of the dry powder composition, and is preferably in the range of about 1.5-12% by weight of the dry powder composition. Sodium bicarbonate and/or sodium carbonate as the alkalizing agent are preferably used in a range of about 2.0% to about 6% by weight of the dry power composition, and more preferably

used in a range of about 2.0% to about 4.5% since above 6% may lead to tackiness problems. When using tri-sodium phosphate as the alkalizing agent, a range of 4.5% to 7% by weight of the dry power composition is preferred for tri-sodium phosphate (anhydrous) and a range of 8% to 12% by weight of the dry power composition is preferred for tri-sodium phosphate (hydrated).

The alkalizing agent acts as an anti-coalescing or stabilizing agent to raise the agglomeration or gel temperature of the coating suspension to prevent coalescing or blockage of the spray lines and guns. The alkalizing agent also reduces the tackiness of the coating.

The solid plasticizer is polyethylene glycol having a molecular weight of 1500 to 8000, or Pluronic F86 (a block co-polymer of ethylene oxide and propylene oxide (EO/PO)), or mixtures thereof. The preferred solid plasticizer is polyethylene glycol 3350 (PEG 3350) or polyethylene glycol 4000 (PEG 4000).

The solid plasticizer when included in the inventive enteric dry powder composition is about 1-20% by weight of the dry coating composition, and is preferably about 1-18% by weight of the dry coating composition.

The liquid plasticizer may be triethylcitrate, glyceryl triacetate, acetyltriethylcitrate, dibutyl sebacate, diethyl phthalate, polyethylene glycol 400, glycerol, castor oil, or mixtures thereof.

5 When the liquid plasticizer is included in the dry powder composition of the invention, the liquid plasticizer is in a range of greater than 0% to about 6% by weight of the dry powder composition. The dry powder composition of the invention is still
10 dry even though it may contain about 4% - 6% liquid plasticizer by weight of the dry powder composition.

 When no plasticizer is included in the dry powder coating composition of the invention or when no liquid plasticizer is included in the dry powder
15 coating composition of the invention, about 5% to about 20% of liquid plasticizer by weight of the dry solid ingredients of the coating suspension of the invention is mixed separately into the coating suspension of the invention.

20 The inventive coating suspension has about 5% to about 20% of solid plasticizer, liquid plasticizer, or a combination of solid plasticizer and liquid plasticizer by weight of the non-water ingredients of the inventive coating suspension.

The lubricant is stearic acid, which is in a range from 0% to about 3% by weight of the dry coating composition.

5 The anti-caking agent may be Cabosil, fumed silica made by Cabot, Inc., which is present in a range from 0% to about 2% by weight of the dry powder composition, and preferably is present in a range from 0% to 1.5% by weight of the dry powder coating composition. The anti-caking agent acts as
10 a processing aid and also keeps the dry powder from lumping up while in storage. Use of this anti-caking agent is optional because any lumps that are formed are screened out as part of the preparation of the dispersion.

15 The pigment may be any of the pigments used in making coating dispersions for pharmaceutical tablets and the like. For example, the pigments may be FD&C and D&C lakes, titanium dioxide, magnesium carbonate, talc, pyrogenic silica, iron oxides,
20 channel black, and insoluble dyes. Also, natural pigments such as riboflavin, carmine 40, curcumin, and annatto. Other examples of suitable pigments are listed in Jeffries U.S. Patent No. 3,149,040; Butler et al. U.S. Patent N .3,297,535; and Colorc n
25 U.S. Patent N . 3,981,984; all f which are incorporated herein by reference.

The pigment may also include lake blends, which contain a plasticizer, and OPADRY pigmented coating compositions, some of which are disclosed in Colorcon U.S. Patent No. 4,543,370 issued on September 24, 1985, which is incorporated herein by reference.

The pigment, in addition to adding color to the coating of the invention, also acts as an anti-gelling agent.

The pigment is in a range from 0% to about 25% by weight of the dry coating composition, and preferably is in a range from 0% to about 15% by weight of the dry powder composition.

The antifoaming agent is a silicone based antifoam, such as Antifoam FG-10 made by Dow Corning. The antifoaming agent is in a range from about 0.1% to about 5% by weight of the dry powder composition, and is preferably about 0.5% to about 5% by weight of the dry powder composition.

The inventive dry powder non-toxic enteric coating composition is to be made and sold by Colorcon, West Point, Pennsylvania 19486, under the trademark SURETERIC.

The following examples further illustrate the invention.

EXAMPLE 1

12 kilograms of aspirin cores (325mg of aspirin per tablet) are to be coated with a clear subcoat made from a clear OPADRY coating dispersion, an enteric coating of the invention over the subcoat, and a pigmented topcoat over the enteric coating, the topcoat being made from an OPADRY II coating dispersion.

The clear OPADRY subcoat dispersion of this Example 1 is made by mixing 120 grams of clear OPADRY coating composition (formula YS-2-7013) into 1480.0 grams of deionized water using a propeller mixer for 45-60 minutes to obtain the subcoat suspension. The subcoat suspension has 7.5% w/w total solids. The OPADRY coating composition is manufactured by Colorcon, West Point, Pennsylvania.

The inventive SURETERIC enteric dry powder composition of this Example 1 is prepared by thoroughly mixing 24.00 grams of the liquid plasticizer, Citroflex triethylcitrate, into 876.00 grams of PVAP-T in a V-blender. Then, 113.52 grams of talc, 40.80 grams of sodium bicarbonate, 96.00 grams of PEG 3350, 21.60 grams of stearic acid, 16.80 grams of sodium alginate, and 11.28 grams of Cabosil EH5 silica is added to the mixture of PVAP-T and liquid plasticizer and mixed into it for about

10 minutes. The mixture then is passed through a grinder, and then mixed again for 10 more minutes.

5 The inventive enteric suspension of the invention is prepared by mixing 1200.0 grams of the inventive enteric dry powder composition into 6800.0 grams of deionized water in a blender for about 1 hour. Before adding the enteric dry powder composition to the water, 12 grams of a 10% Antifoam FG-10 solution is mixed into the 6800.0 grams of
10 distilled water. The total solids in the enteric suspension is 15.0% w/w.

The pigmented OPADRY II topcoat suspension is prepared by mixing 360.0 grams of pigmented OPADRY II coating composition (formula Y-22-13570) into
15 1440.0 grams of distilled water using a propeller mixer for 45-60 minutes. The total solids in the topcoat suspension is 20% w/w. The pigmented OPADRY II coating composition is made by Colorcon, West Point, Pennsylvania.

20 The enteric suspension is passed through a 60 mesh screen prior to commencement of spraying.

The 12 kilograms of aspirin cores (352 mg of aspirin per tablet) are placed in a 24 inch Accela-Cota pan, which has 4 mixing baffles, a Cole-Parmer
25 Masterflex pump having 2 pump heads, Silicone 7015 tubing, 2 Binks 605 spray guns, 66SS fluid nozzles,

and 66SH air caps, for coating. The tablets are first given a subcoat using a clear OPADRY subcoat suspension, followed by an enteric coating with the enteric suspension of this Example 1, which is followed by a topcoat of the pigmented OPADRY II topcoat suspension. The spraying conditions are as follows:

		SUBCOAT	ENTERIC COAT	TOP COAT
10	TABLET LOAD (kg)	12	12	12
	FLUID RATE (g/min)	60	70	60
	ATOMIZING AIR (psi)	35	35	35
	AIR TEMPERATURE (°C)			
	INLET	70	69	67
15	EXHAUST	43	41	43
	PAN SPEED (rpm)	15	15	15
	COATING TIME (min)	27	114	30
	POST DRYING	none	none	none
	% WEIGHT GAIN	1	10	3

The final coated tablets were evaluated using a modified U.S.P. disintegration method. 50 tablets were stressed for 100 revolutions in a fibrillator. Then, the 50 stressed tablets were placed in a basket assembly and immersed for 1 hour in simulated gastric fluid. The basket was moved up and down in the simulated gastric fluid at a rate of about 28-32

strokes/min.

50 unstressed tablets were also placed in a basket assembly and immersed for 1 hour in simulated gastric fluid. The basket was moved up and down in the simulated gastric fluid at a rate of about 28-32 strokes/min.

The integrity of the tablets was evaluated after removal from the simulated gastric fluid. None of the tablets exhibited signs of bloating, cracks, or fissures.

The results of the tests are as follows:

UNSTRESSED: 0% FAILURE

STRESSED: 0% FAILURE

A dissolution test was also made on the coated tablets of this Example 1. Using U.S.P. apparatus I (baskets), 6 tablets coated as described in this Example 1 were placed in 0.1N HCL for 2 hours. The release in the acid phase of the test after 2 hours was 0.31%, as compared with the upper limit of not more than 10%. The 6 tablets were then placed in 6.8 phosphate buffer, and the amount of aspirin released in the buffer phase of the test was greater than 85% in thirty minutes, as compared with the official compendial requirement of not less than 80% in 90 minutes. These test results are illustrated in the graph shown in Fig. 1.

EXAMPLE 2

12 kilograms of Diclofenac sodium cores (75mg Diclofenac sodium per tablet) are to be coated with a clear subcoat made from a clear OPADRY coating dispersion, an enteric coating of the invention over the subcoat, and a clear topcoat over the enteric coating, the topcoat also being made from an OPADRY coating dispersion. Diclofenac sodium cores are alkaline substrates, and it is very difficult to coat alkaline substrates with an enteric coating.

The clear OPADRY subcoat dispersion and the clear OPADRY topcoat dispersion of this Example 2 are each made by mixing 120 grams of clear OPADRY coating composition (formula YS-2-7013) into 1480.0 grams of deionized water using a propeller mixer for 45-60 minutes to obtain the subcoat and topcoat suspensions. The subcoat suspension and the topcoat suspension each have 7.5% w/w total solids. The OPADRY coating composition is manufactured by Colorcon, West Point, Pennsylvania.

The inventive SURETERIC enteric dry powder composition of this Example 2 is prepared by thoroughly mixing 24.00 grams of the liquid plasticizer, Citroflex triethylcitrate, 876.00 grams of PVAP-T in a V-blender. Then, 113.52 grams of talc, 40.80 grams of sodium

bicarbonate, 96.00 grams of PEG 3350, 21.60 grams of stearic acid, 16.80 grams of sodium alginate, and 11.28 grams of Cabosil EH5 silica are added to the mixture of PVAP-T and liquid plasticizer and mixed into the mixture for about 10 minutes. The mixture then is passed through a grinder, and then mixed again for 10 more minutes.

The inventive enteric suspension of the invention is prepared by mixing 1200.0 grams of the inventive enteric dry powder composition into 6800.0 grams of deionized water in a blender for about 1 hour. Before adding the enteric dry powder composition to the water, 12 grams of a 10% Antifoam FG-10 solution is mixed into the 6800.0 grams of distilled water. The total solids in the enteric suspension is 15.0% w/w.

The enteric suspension is passed through a 60 mesh screen prior to commencement of spraying.

The 12 kilograms of Diclofenac sodium cores (75 mg Diclofenac sodium per tablet) are placed in a 24 inch Accela-Cota pan, which has 4 mixing baffles, a Cole-Parmer Masterflex pump having 2 pump heads, Silicone 7015 tubing, 2 Binks 605 spray guns, 66SS fluid nozzles, and 66SH air caps, for coating. The tablets are first given a subcoat using the clear OPADRY subcoat suspension, followed by an enteric

coating with an enteric suspension of this Example 2, which is followed by a topcoat of the OPADRY suspension. The spraying conditions are as follows:

		SUBCOAT	ENTERIC COAT	TOP COAT
5	TABLET LOAD (kg)	12	12	12
	FLUID RATE (g/min)	60	70	60
	ATOMIZING AIR (psi)	35	35	35
	AIR TEMPERATURE (°C)			
10	INLET	74	72	72
	EXHAUST	43	41	43
	PAN SPEED (rpm)	15	15	15
	COATING TIME (min)	27	114	27
	POST DRYING	none	none	none
15	% WEIGHT GAIN	1	10	3

The final coated tablets were evaluated using a modified U.S.P. disintegration method. 50 tablets were stressed for 100 revolutions in a friabilator. Then, the 50 stressed tablets were placed in a basket assembly and immersed for 1 hour in simulated gastric fluid. The basket was moved up and down in the simulated gastric fluid at a rate of about 28-32 strokes/min.

50 unstressed tablets were also placed in a basket assembly and immersed for 1 hour in simulated gastric fluid. The basket was moved up and down in

the simulated gastric fluid at a rate of about 28-32 strokes/min.

The integrity of the tablets was evaluated after removal from the simulated gastric fluid. None of the tablets exhibited signs of bloating, cracks, or fissures.

The results of the tests are as follows:

UNSTRESSED: 0% FAILURE

STRESSED: 0% FAILURE

Six of the 50 stressed tablets from the simulated gastric fluid dissolution test and six of the 50 unstressed tablets from the simulated gastric dissolution test were placed in a basket assembly and immersed for one hour in simulated intestinal fluid. The basket was moved up and down in the simulated intestinal fluid at a rate of about 28-32 strokes per minute. The six stressed tablets and the six unstressed tablets all disintegrated within 8 minutes.

Examples 3-93 further illustrate the invention, all percentages being by weight. In examples 3, 5-9, 11-21, 24, 27, 28, 32-44, 52, 61, and 62, the components of each formulation are mixed together, formed into an enteric coating suspension, and applied to tablets, as in Examples 1 and 2.

In Examples 4, 10, 23, 29-32, 45-51, 53-60, and 80-93, the components of the formulations are dry mixed together to form the enteric dry powder composition, and then the enteric dry powder composition is formed into an enteric coating suspension and applied to tablets as in Examples 1 and 2.

In Examples 22, 25, 26, and 63-79, the dry components are mixed together to form the enteric dry powder composition, which is added to water containing antifoam and the liquid plasticizer of the example.

[illegible]

SURETHERIC FORMULATIONS									
Raw Material	# 13	# 14	# 15	# 16					
PVAP - T	75.00	74.00	73.00	73.00					
Talc 400	8.00	8.00	8.80	8.80					
Stearic Acid	1.80	2.00	1.80	1.30					
Sodium Alginate	1.40	1.50	1.40	1.40					
PEG 3350	7.80	8.00	8.00	8.00					
Citroflex - 2	2.20	2.00	2.00	2.00					
Sodium bicarbonate		3.40	3.40	3.40					
Sodium Hydroxide	2.00								
Cabosil EH6	1.00	0.00	1.50	2.00					
Total	100.00	100.00	100.00	100.00					

SURETERIC FORMULATIONS									
Raw Material	# 22	# 23	#24	# 25	# 26	#27	# 28		
PVAP - J	78.50	65.00	65.00	71.00	61.00	68.00	73.00		
Talc 400	8.00	8.00	8.00	8.00	11.00	8.50	10.50		
Stearic Acid		1.50	1.50	1.50	1.50	1.30	1.70		
Sodium Alginate	1.50	1.40	1.50	1.40	1.50				
HPMC E-50						7.00			
HEC (Natrosol 250 HR)							0.50		
PEG 3350		20.00	18.00	12.50		8.00	8.00		
Citroflex - 2	*11.95	0.00	0.50	* 5.00	* 20.00	2.00	2.00		
Tri Sodium Phosphate	12.00								
Sodium bicarbonate		3.20	3.20	3.40	3.80	3.40	3.40		
Cabosil EH 5		0.90	1.00	0.90	0.90	1.00	0.90		
Total	100.00	100.00	100.00	100.00	100.00	100.00	100.00		
Citroflex - 2 (Triacetin) will be added to the dispersion externally									

SURETERIC FORMULATIONS

Raw Materials	#29	#30	#31	#32	#33	#34	#35
PVAP - T	68.00	69.00	69.00	73.50	74.10	73.00	73.00
Talc 400	—	—	8.88	9.14	10.00	9.46	9.46
Aluminium Hydrate	10.30	8.65	—	—	—	—	—
Stearic Acid	2.80	1.90	1.76	1.72	1.80	1.80	1.80
Sodium Alginate	1.40	1.40	1.33	1.42	1.44	1.40	1.40
PEG 3350	10.36	9.28	6.65	9.30	7.20	—	—
Pluronic F68	—	—	3.00	—	—	—	—
PEG 4000	—	—	—	—	—	—	8.00
PEG 8000	—	—	—	—	—	8.00	—
Citroflex - 2	—	—	—	—	2.00	2.00	2.00
Sodium Bicarbonate	—	—	—	—	—	3.40	3.40
Sodium Carbonate	—	—	—	4.00	2.50	—	—
TSP 12H ₂ O	6.10	8.80	8.49	—	—	—	—
Cabosil EH 5	0.94	0.97	0.89	0.92	0.96	0.94	0.94
Total	100.00	100.00	100.00	100.00	100.00	100.00	100.00

Raw Material	#17	Pigment Blend		#19	#20	#21
PVAP - J	73.00	Raw Material	#18	—	—	—
Talc 400	9.46	Lake Blend 1368	55.00	9.46	9.46	9.46
Stearic Acid	1.80	TiO ₂	20.00	1.80	1.80	1.80
Sodium Alginate	1.40	PEG 3350	10.00	1.40	1.40	1.40
PEG 3350	8.00	Citroflex - 2	10.00	8.00	8.00	8.00
Citroflex - 2	2.00	Tween 80	3.00	2.00	2.00	2.00
Sodium bicarbonate	3.40			3.40	3.40	3.40
Cabosil EH 5	0.94			0.94	0.94	0.94
HPMCP	—			73.00	—	—
HPMGAS	—			—	73.00	—
CAP ..	—			—	—	73.00
Total	100.00		100.00	100.00	100.00	100.00

Raw Material	#18A	#18B
#17 Sureteric clear	94.00	87.50
#18 Pigment Blend	6.00	12.50

[illegible]

Components	EX. 56	EX. 57	EX. 58	EX. 59	EX. 60	EX. 61	EX. 62
%PVAPJ							
%PVAPT	68.03	72.6	73.55	74	73.5	73	73.2
%TALD		8.54	7.84	8.1	8.14	8.48	8.48
% Al. Hydrate	8.08						
%Stearic acid		1.78	1.72	1.75	1.72	1.8	1.8
%So. Alcohols	1.38	1.4	1.43	1.42	1.42	1.4	1.4
%Cetanol	0.91	0.9	0.88	0.92	0.92	0.94	0.94
%So. Fats	8.3	8	4.83				
%Cholesterol						2.3	2.4
% Sod. Bicarb						4	3.6
%PEG 3350	8.34	8.8	8.07	8.3	8.3	7.1	7.2
% Sod. Carb.				2.54	4		
%Phenolic FBS	2						
% Mg. Oxide		1.2	1.2	0.97			
% PG - 10	1	1	1	1	1	1	1

Components	EX. 63	EX. 64	EX. 65	EX. 66
%PVAP-J				
%PVAP-T	80.84	80.84	78.1	78.41
%TALC	10.33	10.33	10.18	8.78
% Al Hydrate				
%Stearic acid	2.08	2.08	2.02	1.98
%So. Alginates	1.54	1.54	1.52	1.47
%Cetanol	1.04	1.04	1.01	0.98
%So. Phos.	4.38 (arib)	4.38(arib)	8.2	8.4
%Cholesterol	10.9	10.9	10.7	10.32
%PEG 3350				
%Pluronic F69				
% FG - 18	1	1	1	1

[illegible]

[illegible]

The percent solids in the enteric coating suspensions of the invention are about 10% to about 30%, and preferably is about 12% to about 20%.

5 It is preferred, but not necessary, to provide a subcoat and a topcoat, such as those described in Examples 1 and 2, on a tablet coated in accordance with the invention. Preferably, the subcoat and the topcoat each comprise, typically, 1-10% of the weight of the tablet, depending on the size, weight, 10 and shape of the tablet. Typically, a small tablet requires a larger percentage of subcoat and topcoat by weight of the tablet than does a larger tablet.

The enteric coating of the invention comprises, typically, greater than 6% of the weight of the 15 tablet, and preferably between 8% to 12% by weight of the tablet in order to get the enteric results, depending on the size, weight, and shape of the tablet. A small tablet requires a larger percentage of coating by weight of the tablet for enteric 20 coating than does a larger tablet.

Tablets coated with the inventive coating suspension have an intestinally soluble coating that is insoluble in the gastric juices of the stomach.

Without the step of adding an antifoaming agent 25 in the method of making the enteric coating suspension of the invention, air bubbles tend to be

incorporated into the suspension during mixing of the dry ingredients into the water. Air bubbles, if present in the coating suspension during spraying onto tablets substrates may create pin holes in the film coating, which may lead to failure of the enteric film coating. Further, some of the alkalizing agents, such as sodium bicarbonate, are effervescent, and mixing them into the water of the enteric coating suspension may lead to the formation of additional air bubbles in the enteric coating suspension. Also, sodium alginate tends to maintain any foam or bubbles formed in the enteric coating suspension. The antifoaming agent fights against the incorporation of air bubbles in the enteric coating suspension by causing air bubbles in the enteric coating suspension to rupture.

The enteric coating of the invention provides an improvement of film properties over the film properties of known enteric film coatings based on aqueous enteric coating suspension. For example, the coating of the invention, when compared with known coatings based on aqueous enteric coating suspensions, has better adhesion, is more resilient, is less friable, and has a significantly lower modulus of elasticity. Further, using a preferred embodiment of the inventive enteric dry powder

composition which contains a plasticizer, our
inventive aqueous enteric coating suspension
requires only two processing steps to form the
enteric coating suspension of the invention - mixing
antifoam with water and then mixing the enteric
powder composition into the antifoam/water mixture.

A comparison of the inventive SURETERIC system
with other enteric aqueous systems appears below.

	SURETERIC	EUDRAGIT	AQUATERIC	COATERIC
PREPARA- TION STEPS	Mix powder & antifoam with water	Mix plast- icizer, antifoam, & talc with dispersion	Mix powder, plast- icizer & Tween 80 with water	Mix powder, antifoam, & ammonia with water
PREPARA- TION STEPS	2	3	3	3
PREPARA- TION TIME	45-60 min.	60 min.	90-110 min.	60 min.
PROCESS PROBLEMS	1. Slight Tack	1. Tack, 2. High % of talc settles rapidly, 3. Prone to gun clogs	1. 60 min. post-drying step	1. Tack, 2. Ammonia unpleasant to work with

CLAIMS

1. A non-toxic edible enteric film coating dry powder composition for use in making an aqueous enteric coating suspension which may be used in coating pharmaceutical tablets and the like, comprising

an enteric film forming polymer,
a detackifier,
a viscosity modifier, and
an alkalizing agent.

2. The enteric film coating dry powder composition of claim 1, further including a solid plasticizer.

3. The enteric film coating dry powder composition of claim 1, further including a lubricant.

4. The enteric film coating dry powder composition of claim 1, further including an anti-caking agent.

5. The enteric film coating dry powder composition of claim 1, further including a liquid plasticizer.

6. The enteric film coating dry powder composition of claim 1, further including a pigment.

5 7. The enteric film coating dry powder composition of claim 1,
the enteric film forming polymer being PVAP-T (titanized polyvinyl acetate phthalate), PVAP-J (polyvinyl acetate phthalate which has been jet milled), HPMCP (hydroxypropyl methylcellulose phthalate), HPMCAS (hydroxypropyl methylcellulose acetate succinate), or CAP (cellulose acetate phthalate).

10 8. The enteric film coating dry powder composition of claim 1,
15 the polymer being in a range of about 55% to about 85% by weight of the composition.

9. The enteric film coating dry powder composition of claim 1,
the polymer being in a range of about 65% to
20 about 81% by weight of the composition.

10. The enteric film coating dry powder composition of claim 1,
the detackifier being talc, aluminum hydrate, or mixtures thereof.

5 11. The enteric film coating dry powder composition of claim 1,
the detackifier being in a range of about 5% to about 15% by weight of the composition.

10 12. The enteric film coating dry powder composition of claim 1,
the detackifier being in a range of about 6% to about 12% by weight of the composition.

15 13. The enteric film coating dry powder composition of claim 1,
the viscosity modifier being sodium alginate, hydroxypropyl methylcellulose (HPMC), hydroxyethylcellulose (HEC), sodium carboxymethylcellulose (sodium CMC), polyvinylpyrrolidone (PVP), Konjac flour,
20 carrageenan, xanthan gum, other hydrophilic polymers, or mixtures thereof.

14. The enteric film coating dry powder composition of claim 1,
the viscosity modifier being in a range of about 0.5% to about 7% by weight of the composition.

5 15. The enteric film coating dry powder composition of claim 1,
the viscosity modifier being in a range of about 1% to about 6% by weight of the composition.

10 16. The enteric film coating dry powder composition of claim 1,
the alkalizing agent being a bicarbonate, a carbonate, a phosphate, or a hydroxide of sodium or potassium, magnesium carbonate, magnesium hydroxide, ammonium carbonate, ammonium bicarbonate, magnesium
15 oxide, calcium hydroxide, or mixtures thereof.

17. The enteric film coating dry powder composition of claim 1,
the alkalizing agent being in a range of about 1% to about 15% by weight of the composition.

18. The enteric film coating dry powder composition of claim 1,
the alkalizing agent being in a range of about 1.5% to about 12% by weight of the composition.

5 19. The enteric film coating dry powder composition of claim 2,
the solid plasticizer being polyethylene glycol having a molecular weight of 1500 to 8000, or Pluronic F86.

10 20. The enteric film coating dry powder composition of claim 2,
the solid plasticizer being in a range of about 1% to about 20% by weight of the composition.

15 21. The enteric film coating dry powder composition of claim 2,
the solid plasticizer being in a range of about 1% to about 18% by weight of the composition.

20 22. The enteric film coating dry powder composition of claim 3,
the lubricant being stearic acid.

23. The enteric film coating dry powder composition of claim 3,
the lubricant being in a range of greater than 0% to about 3% by weight of the composition.

5 24. The enteric film coating dry powder composition of claim 4,
the anti-caking agent being silica.

25. The enteric film coating dry powder composition of claim 4,
10 the anti-caking agent being in a range of greater than 0% to about 2% by weight of the composition.

26. The enteric film coating dry powder composition of claim 4,
15 the anti-caking agent being in a range of greater than 0% to about 1.5% by weight of the composition.

27. The enteric film coating dry powder composition of claim 5,

the liquid plasticizer being triethylcitrate, glyceryl triacetate, acetyltriethylcitrate, dibutyl sebacate, diethyl phthalate, polyethylene glycol 400, glycerol, castor oil, or mixtures thereof.

28. The enteric film coating dry powder composition of claim 5,

the liquid plasticizer being in a range of greater than 0 to about 6% by weight of the composition.

29. The enteric film coating dry powder composition of claim 6,

the pigment being lake blends with plasticizer, FD&C and D&C lakes, titanium dioxide, or OPADRY non-clear film coating compositions.

30. The enteric film coating dry powder composition of claim 6,

the pigment being in a range from greater than 0% to about 25% by weight of the composition.

31. The enteric film coating dry powder composition of claim 6,
the pigment being in a range from greater than 0% to about 15% by weight of the composition.

5 32. The enteric film coating dry powder composition of claim 2, further including
a lubricant,
an anti-caking agent,
a liquid plasticizer, and
10 a pigment,
the enteric film forming polymer being
PVAP-T (titanized polyvinyl acetate phthalate),
PVAP-J (polyvinyl acetate phthalate which has been
jet milled), HPMCP (hydroxypropyl methylcellulose
15 phthalate), HPMCAS (hydroxypropyl methylcellulose
acetate succinate), or CAP (cellulose acetate
phthalate),

the polymer being in a range of about 65% to about 81% by weight of the composition,

20 the detackifier being talc, aluminum hydrate, or mixtures thereof,

the detackifier being in a range of about 6% to about 12% by weight of the composition,

the viscosity modifier is sodium alginate,
hydroxypropyl methylcellulose (HPMC),
hydroxyethylcellulose (HEC), sodium
carboxymethylcellulose (sodium CMC),
5 polyvinylpyrrolidone (PVP), Konjac flour,
carrageenan, xanthan gum, other hydrophilic
polymers, or mixtures thereof,

the viscosity modifier being in a range of
about 1% to about 6% by weight of the composition,

10 the alkalizing agent being a bicarbonate, a
carbonate, a phosphate, or a hydroxide of sodium or
potassium, magnesium carbonate, magnesium hydroxide,
ammonium carbonate, ammonium bicarbonate, magnesium
oxide, calcium hydroxide, or mixtures thereof,

15 the alkalizing agent being in a range of about
1.5% to about 12% by weight of the composition,

the solid plasticizer being polyethylene glycol
3350, polyethylene glycol 1800, polyethylene glycol
4000, or polyethylene glycol 8000,

20 the solid plasticizer being in a range of about
1% to about 18% by weight of the composition,

the lubricant being stearic acid,

the lubricant being in a range of greater than
0% to about 3% by weight of the composition,

25 the anti-caking agent being silica,

the anti-caking agent being in a range of greater than 0% to about 1.5% by weight of the composition,

5 the liquid plasticizer being triethylcitrate, glyceryl triacetate, acetyltriethylcitrate, dibutyl sebacate, diethyl phthalate, polyethylene glycol 400, glycerol, castor oil, or mixtures thereof.

10 the liquid plasticizer being in a range of greater than 0% to about 6% by weight of the composition,

the pigment being lake blends with plasticizer, FD&C and D&C lakes, titanium dioxide, or OPADRY non-clear film coating compositions,

15 the pigment being in a range from greater than 0% to about 15% by weight of the composition.

33. A non-toxic edible aqueous enteric coating suspension for use in coating pharmaceutical tablets and the like, comprising

20 an enteric film forming polymer,
a detackifier,
a viscosity modifier,
an alkalizing agent,
a plasticizer,
an antifading agent,
25 and water.

34. The enteric coating suspension of claim 33,

the plasticizer being a solid plasticizer, a liquid plasticizer, or a combination thereof.

5 35. The enteric coating suspension of claim 33, further including a lubricant.

10 36. The enteric coating suspension of claim 33, further including an anti-caking agent.

37. The enteric coating suspension of claim 33, further including a pigment.

15 38. The enteric coating suspension of claim 33,

the enteric film forming polymer being PVAP-T (titanized polyvinyl acetate phthalate), PVAP-J (polyvinyl acetate phthalate which has been jet milled), HPMCP (hydroxypropyl methylcellulose phthalate), HPMCAS (hydroxypropyl methylcellulose acetate succinate), or CAP (cellulose acetate phthalate).

20

39. The enteric coating suspension of claim
33,

the polymer being in a range of about 55% to
about 90% by weight of the non-water ingredients of
the suspension.

40. The enteric coating suspension of claim
33,

the polymer being in a range of about 65% to
about 81% by weight of the non-water ingredients of
the suspension.

41. The enteric coating suspension of claim
33,

the detackifier being talc, aluminum hydrate,
or mixtures thereof.

42. The enteric coating suspension of claim
33,

the detackifier being in a range of about 5% to
about 15% by weight of the non-water ingredients of
the suspension.

43. The enteric coating suspension of claim
33,

the detackifier being in a range of about 6% to
about 12% by weight of the non-water ingredients of
the suspension.

44. The enteric coating suspension of claim
33,

the viscosity modifier being sodium alginate,
HPMC (hydroxypropyl methylcellulose), HEC
(hydroxyethylcellulose), sodium CMC (sodium
carboxymethylcellulose), PVP
(polyvinylpyrrolidone), Konjac flour, carrageenan,
xanthan gum, other hydrophilic polymers, or mixtures
thereof.

45. The enteric coating suspension of claim
33,

the viscosity modifier being in the range of
about 0.5% to about 7% by weight of the non-water
ingredients of the suspension.

46. The enteric coating suspension of claim 33,

the viscosity modifier being in the range of about 1% to about 6% by weight of the non-water ingredients of the suspension.

47. The enteric coating suspension of claim 33,

the alkalizing agent being a bicarbonate, a carbonate, a phosphate, or a hydroxide of sodium or potassium, magnesium carbonate, magnesium hydroxide, ammonium carbonate, ammonium bicarbonate, magnesium oxide, calcium hydroxide, or mixtures thereof.

48. The enteric coating suspension of claim 33,

the alkalizing agent being in a range of about 1% to about 15% by weight of the non-water ingredients of the suspension.

49. The enteric coating suspension of claim 33,

the alkalizing agent being in a range of about 1.5% to about 12% by weight of the non-water ingredients of the suspension.

50. The enteric coating suspension of claim
34,

the solid plasticizer being polyethylene glycol
having a molecular weight between 1500 and 8000, or
Pluronic F86.

51. The enteric coating suspension of claim
34,

the solid plasticizer being in a range of about
1% to about 20% by weight of the non-water
ingredients of the suspension.

52. The enteric coating suspension of claim
34,

the solid plasticizer being in the range of
about 1% to about 18% by weight of the non-water
ingredients of the suspension.

53. The enteric coating suspension of claim
35,

the lubricant being stearic acid.

54. The enteric coating suspension of claim
35,

the lubricant being in a range of greater than
0% to about 3% by weight of the non-water
5 ingredients of the suspension.

55. The enteric coating suspension of claim
36,

the anti-caking agent being silica.

56. The enteric coatings suspension of claim
10 36,

the anti-caking agent being in a range of
greater than 0% to about 2% by weight of the
non-water ingredients of the suspension.

57. The enteric coating suspension of claim
15 36,

the anti-caking agent being in a range of
greater than 0% to about 1.5% by weight of the
non-water ingredients of the suspension.

58. The enteric coating suspension of claim
34,

the liquid plasticizer being triethylcitrate,
glyceryl triacetate, acetyltriethylcitrate, dibutyl
5 sebacate, diethyl phthalate, polyethylene glycol
400, glycerol, castor oil, or mixtures thereof.

59. The enteric coating suspension of claim
34,

10 the liquid plasticizer being in a range of
greater than 0% to about 6% by weight of the
non-water ingredients of the suspension.

60. The enteric coating suspension of claim
34,

15 the liquid plasticizer being in a range of
about 5% to about 20% by weight of the dry solid
ingredients of the suspension.

61. The enteric coating suspension of claim
37,

20 the pigment being lake blends with plasticizer,
FD&C and D&C lakes, titanium dioxide, or OPADRY non-
clear film coating compositions.

62. The enteric coating suspension of claim
37,

the pigment being in a range from greater than
0% to about 25% by weight of the non-water
ingredients of the suspension.

63. The enteric coating suspension of claim
37,

the pigment being in a range from greater than
0% to about 15% by weight of the non-water
ingredients of the suspension.

64. The enteric coating suspension of claim
33,

the antifoaming agent being a silicone based
antifoam.

65. The enteric coating suspension of claim
33,

the antifoaming agent being in a range of about
0.1% to about 5% by weight of the non-water
ingredients of the suspension.

66. The enteric coating suspension of claim
33,

the antifoaming agent being in a range of about
0.5% to about 5% by weight of the non-water
ingredients of the suspension.

67. The enteric coating suspension of claim
34, further including

lubricant,
an anti-caking agent,
and a pigment,

the enteric film forming polymer being PVAP-T
(titanized polyvinyl acetate phthalate), PVAP-J
(polyvinyl acetate phthalate which has been jet
milled), HPMCP (hydroxypropyl methylcellulose
phthalate), HPMCAS (hydroxypropyl methylcellulose
acetate succinate), or CAP (cellulose acetate
phthalate),

the polymer being in a range of about 65% to
about 81% by weight of the non-water ingredients of
the suspension,

the detackifier being talc, aluminum hydrate,
or mixtures thereof,

the detackifier being in a range of about 6% to
about 12% by weight of the non-water ingredients of
the suspension,

the viscosity modifier being sodium alginate, HPMC (hydroxypropyl methylcellulose), HEC (hydroxyethylcellulose), sodium CMC (sodium carboxymethylcellulose), PVP (polyvinylpyrrolidone),
5 Konjac flour, carrageenan, xanthan gum, other hydrophilic polymers, or mixtures thereof,

the viscosity modifier being in a range of about 1% to about 6% by weight of the non-water ingredients of the suspension,

10 the alkalizing agent being a bicarbonate, a carbonate, a phosphate, or a hydroxide of sodium or potassium, magnesium carbonate, magnesium hydroxide, ammonium carbonate, ammonium bicarbonate, magnesium oxide, calcium hydroxide, or mixtures thereof,

15 the alkalizing agent being in a range of about 2% to about 14% by weight of the non-water ingredients of the suspension,

the plasticizer being in a range of about 5% to about 20% by weight of the non-water ingredients of
20 the suspension,

the solid plasticizer being polyethylene glycol 1500, polyethylene glycol 3350, polyethylene glycol 4000, polyethylene glycol 8000, or Pluronic F86,

the liquid plasticizer being triethylcitrate,
glyceryl triacetate, acetyltriethylcitrate, dibutyl
sebacate, diethyl phthalate, polyethylene glycol
400, glycerol, castor oil, or mixtures thereof,

5 the lubricant being stearic acid,

the lubricant being in a range of greater than
0% to about 3% by weight of the non-water
ingredients of the suspension,

the anti-caking agent being silica,

10 the anti-caking agent being in a range of a
greater than 0% to about 1.5% by weight of the
non-water ingredients of the suspension,

the pigment being lake blends with plasticizer,
FD&C and D&C lakes, titanium dioxide, or OPADRY
non-clear film coating compositions,

15 the pigment being in a range from greater than
0% to about 15% by weight of the non-water
ingredients of the suspension,

the antifoaming agent being a silicon based
antifoam,

20 the antifoaming agent being in a range from
about 0.5% to about 5% by weight of the non-water
ingredients of the suspension.

68. A method of coating substrates such as pharmaceutical tablets and the like with an enteric film coating, comprising

mixing an antifoaming agent into water,

5 mixing an enteric film forming polymer, a detackifier, a viscosity modifier, an alkalizing agent, and a plasticizer into the water to form an aqueous enteric coating suspension,

10 applying the aqueous enteric coating suspension onto the substrates to form an enteric film coating on the substrates, and

drying the enteric film coating on said substrates.

69. The method of claim 68, further including
15 the step of mixing a lubricant into the water.

70. The method of claim 68, further including the step of

mixing an anti-caking agent into the water.

71. The method of claim 68, further including
20 the step of

mixing a pigment into the water.

72. The method of claim 68, further including the step of

mixing a lubricant, an anti-caking agent, and a pigment into the water,

5 the enteric film forming polymer being PVAP-T (titanized polyvinyl acetate phthalate), PVAP-J (polyvinyl acetate phthalate which has been jet milled), HPMCP (hydroxypropyl methylcellulose phthalate), HPMCAS (hydroxypropyl
10 methylcellulose acetate succinate), or CAP (cellulose acetate phthalate),

the polymer being in a range of about 65% to about 81% by weight of the non-water ingredients of the suspension,

15 the detackifier being talc, aluminum hydrate, or mixtures thereof,

the detackifier being in a range of about 6% to about 12% by weight of the non-water ingredients of the suspension,

20 the viscosity modifier being sodium alginate, HPMC (hydroxypropyl methylcellulose), HEC (hydroxyethylcellulose), sodium CMC (sodium carboxymethylcellulose), PVP (polyvinyl pyrrolid n), Konjac flour, carrageenan, xanthan
25 gum, other hydr philic p lym rs, r mixtur s thereof,

the viscosity modifier being in a range of about 1% to about 6% by weight of the non-water ingredients of the suspension,

5 the alkalizing agent being a bicarbonate, a carbonate, a phosphate, or a hydroxide of sodium or potassium, magnesium carbonate, magnesium hydroxide, ammonium carbonate, ammonium bicarbonate, magnesium oxide, calcium hydroxide, or mixtures thereof,

10 the alkalizing agent being in the range of about 1.5% to about 12% by weight of the non-water ingredients of the suspension,

the plasticizer being in a range of about 5% to about 20% by weight of the non-water ingredients of the suspension,

15 the plasticizer being a solid plasticizer, a liquid plasticizer, or a combination thereof,

the solid plasticizer being polyethylene glycol 1500, polyethylene glycol 3350, polyethylene glycol 4000, polyethylene glycol 8000, or Pluronic F86,

20 the liquid plasticizer being triethylcitrate, glyceryl triacetate, acetyltriethylcitrate, dibutyl sebacate, diethyl phthalate, polyethylene glycol 400, glycerol, castor oil, or mixtures thereof,

the lubricant being stearic acid,

the lubricant being in a range greater than 0% to about 3% by weight of the non-water ingredients of the suspension,

the anti-caking agent being silica,

5 the anti-caking agent being in a range of greater than 0% to about 1.5% by weight of the non-water ingredients of the suspension,

the pigment being lake blends with plasticizer, FD&C and D&C lakes, titanium dioxide, or OPADRY non-clear film coating compositions,


10 the pigment being in a range from greater than 0% to about 15% by weight of the non-water ingredients of the suspension,

the antifoaming agent being a silicone based antifoam, and

15 the antifoaming agent being in a range of about 0.5% to about 5% by weight of the non-water ingredients of the suspension.

1/1

Figure 1: Formula X-08314/Topcoat Y-22-13570
Substrate: 325 mg Aspirin Cores
Dissolution: U.S.P. Method I Delayed Release



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/12934**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :A61K 9/36

US CL :424/480

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/480, 489, 486 and 440

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 4,704,295 (PORTER ET AL) 03 November 1987, See entire document.	1-72

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

16 JANUARY 1996

Date of mailing of the international search report

01 FEB 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

William E. Benston, Jr.

Facsimile No. (703) 305-3230

Telephone No. (703) 308-2351